Cantor Fitzgerald Maintains Overweight on LifeMD, Raises Price Target to $9
Portfolio Pulse from Benzinga Newsdesk
Cantor Fitzgerald analyst Sarah James has maintained an Overweight rating on LifeMD (NASDAQ:LFMD) and increased the price target from $8 to $9.
November 14, 2023 | 5:19 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Cantor Fitzgerald analyst Sarah James reaffirmed an Overweight rating on LifeMD and raised the price target to $9, indicating a positive outlook on the stock.
The increase in price target by a reputable analyst typically signals a positive forecast for the company's stock performance and can lead to increased investor confidence, potentially driving the stock price up in the short term.
CONFIDENCE 90
IMPORTANCE 85
RELEVANCE 100